MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$187,362K
Exercise of stock options
$7,803K
Proceeds from employee
stock purchase plan
$923K
Net cash provided by
financing activities
$196,088K
Net change in cash
and cash...
$19,482K
Canceled cashflow
$176,606K
Stock-based compensation
$34,752K
Accrued compensation
$2,374K
Depreciation
$2,084K
Accrued other expenses
and other...
$691K
Accounts payable
$272K
Amortization of right-of-use
asset
$182K
Maturities of marketable
securities
$427,308K
Sales of marketable
securities
$67,384K
Net cash used in
operating activities
-$143,816K
Net cash (used in)
provided by investing...
-$32,790K
Canceled cashflow
$40,355K
Canceled cashflow
$494,692K
Net loss
-$167,795K
Purchases of marketable
securities
$527,226K
Prepaid expenses and
other assets
$7,963K
Accretion of discount on
marketable securities, net
$7,665K
Lease liability
-$748K
Purchases of property and
equipment
$256K
Back
Back
Cash Flow
source: myfinsight.com
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)